Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 earnings review
Vanda cuts quarterly trial costs, but lowers its sales ceiling
Vanda Pharmaceuticals, a maker of psychiatric and sleep-disorder medicines, grew sales and cut quarterly spending while scaling back its full-year revenue ambition. Reported revenue jumped 24%, or 12% by our math without a delayed June shipment of HETLIOZ, as Fanapt prescriptions rose. Chief executive Mihael Polymeropoulos cut operating expenses by 18% from last quarter as late-stage trials wrapped up, narrowing the net loss to $23 million.
| Revenue excluding delayed June shipment | $62.8M +12% from a year ago by our math (reported: $69.8M, +24%) |
|---|---|
| Total operating expenses | $93.3M -18% from last quarter |
| Cash and marketable securities | $140.5M down $29.5M in Q3 |
| Full-year 2026 revenue outlook | Cut to >$240M prior: $240M–$290M |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because lower trial spending and two Phase III wins were offset by a watered-down revenue plan and a later launch for BYSANTI. Dropping the $290 million top end of the 2026 outlook and removing individual product targets admits the steep second-half sales ramp will not happen this year. One positive: quarterly cash burn slowed to $30 million, giving the $141 million cash pile slightly more breathing room.
The question now is whether Vanda can switch Fanapt patients to BYSANTI and ramp NEREUS fast enough to close its funding gap before Fanapt loses patent protection at the end of 2027. Either fourth-quarter launches lift revenue toward the old $265 million target while trial costs keep falling, or slow uptake keeps the company burning cash down toward a dilutive capital raise. Fourth-quarter BYSANTI sales and the December 12 FDA decision on Quimilza will tell.
🐂 Bull Case
Operating Costs Fell 18% From Last Quarter
Vanda has spent heavily over the past two years on late-stage clinical trials and commercial launches, pushing the business into deep losses. Chief executive Mihael Polymeropoulos said third-quarter operating expenses dropped 18% from the second quarter "as key Phase III and launch-preparation activities conclude." The drugmaker said it "expects operating expenses to decrease further in future quarters, as the remainder of these activities conclude."
- Total operating expenses: $93.3 million, down 18.4% from last quarter and up 6.6% from a year ago
- Selling, general and administrative costs (sales force, advertising and overhead): $59.6 million, or 85.3% of revenue, down 21.8 percentage points from a year ago by our math
- Research and development costs: $27.6 million, or 39.6% of revenue, down 33.6 percentage points from last quarter by our math
- Loss from operations: $23.5 million, narrower than the $63.8 million loss last quarter
This spending drop matters because the biopharmaceutical group had been burning through its cash reserves to fund three product launches at once. Lower trial bills cut the quarterly operating loss by nearly two-thirds from the second quarter, proving management can pull back spending once studies finish.
What to watch: fourth-quarter operating expenses when full-year results arrive in early 2027. A further drop despite the planned fourth-quarter launch of BYSANTI would confirm that commercial overhead has peaked.
Two Positive Late-Stage Trials Expand the Pipeline
Vanda is trying to build a broader portfolio of six commercial drugs by the end of 2026 so it relies less on older medicines. In October, the company announced positive Phase III trial results for NEREUS, its newly launched motion-sickness pill, to prevent vomiting caused by GLP-1 weight-loss and diabetes drugs. In September, HETLIOZ, its sleep-disorder drug, also succeeded in a pivotal trial for Delayed Sleep-Wake Phase Disorder.
These clinical wins give both drugs a shot at much larger patient groups, while the Food and Drug Administration reviews Quimilza, an antibody treatment for a rare skin disease called generalized pustular psoriasis, ahead of a December 12, 2026 decision date. Meanwhile, NEREUS sales rose 60% from last quarter to $1.6 million after Vanda's sales force began promoting it to doctors in the third quarter.
What to watch: the FDA decision on Quimilza on December 12, 2026, and supplemental application filings for NEREUS and HETLIOZ. Approval of Quimilza would give the drugmaker a fourth commercial franchise without new trial spending.
Fanapt Prescriptions Keep Outpacing Price Pressure
Fanapt, an oral pill for schizophrenia and bipolar disorder, is Vanda's largest product and carries the business while newer drugs launch. Bears have worried that higher Medicare rebates and co-pay assistance were eating into the price Vanda keeps per prescription. In the third quarter, Fanapt sales grew 24.1% from a year ago to $38.8 million, nearly matching the 25% rise in total prescriptions.
That 1-point gap between prescription growth and revenue growth narrowed from an 8-point gap in the second quarter, so price discounts did not worsen this period. New-to-brand prescriptions rose 18% from a year ago and are up 306% since the second quarter of 2024, showing the expanded sales force still brings in new patients.
What to watch: fourth-quarter Fanapt prescription growth against net sales growth. If net revenue keeps tracking within a few points of prescription volume, the Medicare rebate drag has stabilized.
🐻 Bear Case
Vanda Dropped the Top End of Its Sales Plan
Polymeropoulos said "we are focused on further moderating costs and driving revenue growth from our current portfolio and planned launches to support sustainable long-term value." Yet in the same release, Vanda dropped the upper end of its 2026 revenue plan, which previously called for $240 million to $290 million, and said it now "expects to achieve total revenue for full year 2026 of greater than $240 million."
- Prior full-year 2026 revenue plan: $240 million to $290 million (middle of the range: $265 million)
- Updated full-year 2026 revenue plan: greater than $240 million
- First nine months revenue: $172.1 million, leaving at least $67.9 million for the fourth quarter by our math
- Removed from the release: separate full-year sales ranges for Fanapt and BYSANTI ($150–170 million), NEREUS ($10–30 million), and other products ($80–90 million)
Removing the $290 million ceiling and the product-by-product targets after nine months of sales shows that the big second-half jump management had planned on is no longer reachable. To hit the old $265 million midpoint, fourth-quarter revenue would have needed to reach $92.9 million by our math, or $30.1 million above the third quarter's underlying run-rate.
What to watch: whether management restores product-level revenue targets on the conference call or in the quarterly filing. Silence on the individual product ranges would confirm that NEREUS and BYSANTI will contribute little revenue this year.
BYSANTI Launch Wait Compresses the Switch Window
Fanapt loses its US protection against cheaper generic copies at the end of 2027, so Vanda's main psychiatric franchise depends on switching patients to BYSANTI, a newly approved schizophrenia and bipolar pill protected by patents until 2044. The FDA approved BYSANTI in February 2026, and management previously said it would launch in the second half of 2026.
The third quarter ended with no commercial launch and zero BYSANTI revenue, as Vanda now expects the launch in the fourth quarter of 2026. That leaves at most five quarters to move patients over before generic Fanapt arrives. Meanwhile, a Phase III trial testing BYSANTI for major depressive disorder has enrolled 55% of its 500-patient target across 54 sites, keeping results in the first half of 2027.
What to watch: standalone BYSANTI sales and prescription numbers in the fourth-quarter report. If Vanda groups BYSANTI sales inside Fanapt revenue instead of reporting them separately, investors will not see whether patients are actually switching.
HETLIOZ Still Shrinks Underneath a Late Shipment
HETLIOZ, Vanda's sleep-disorder medicine facing generic competition, appeared to rebound in the third quarter with reported sales up 20.6% from a year ago to $21.7 million. However, Vanda noted that the figure "includes orders totaling approximately $7.0 million in revenue that were shipped on June 29, 2026 and arrived on July 1, 2026."
Excluding that delayed June shipment, third-quarter HETLIOZ sales were about $14.7 million by our math, down 18.3% from $18.0 million a year ago. For the first nine months of 2026, which smooths out the quarter-end shipping quirk, HETLIOZ revenue fell 21.5% from a year ago to $43.2 million, confirming that generic substitution continues to erode the brand.
What to watch: fourth-quarter HETLIOZ net sales without shipping delays, and the December 14–18, 2026 administrative judge hearing on its jet-lag application. A drop below $14 million would show generic erosion is still costing over $3 million a quarter.
Cash Burn Slowed, but Cash Is Down to $141 Million
Vanda has funded its pipeline expansion and legal battles out of its cash pile, which has fallen by $123.4 million over the first nine months of 2026. In the third quarter, cash and marketable securities dropped by $29.5 million to $140.5 million, a slower burn than the $32.3 million outflow in the second quarter, while several standing operational risks remained unresolved in the release.
- Cash and marketable securities: $140.5 million at September 30, 2026, or under five quarters of runway at the third-quarter burn rate by our math
- PONVORY (multiple sclerosis pill): sales of $7.7 million, down 2.3% from last quarter, with no update on previously disputed revenue allowances
- NEREUS channel inventory: $1.6 million recognized in Q3, with no release disclosure on how much of Q2's $12.6 million constrained wholesaler stock sold through
- Long-acting Fanapt trial and customer concentration: no enrollment update or customer breakdown in the release; the 10-Q filing will carry channel details
What to watch: year-end cash and the NEREUS inventory constraint note in the upcoming 10-Q filing. If quarterly cash burn does not fall below $20 million as trials wrap up, Vanda will face pressure to raise outside capital before Fanapt loses exclusivity.
💲 Other KPIs
Vanda's balance-sheet reserve for product rebates, discounts and returns rose 22.8% from $76.9 million at the end of 2025, though it barely moved from $94.0 million last quarter. Product revenue allowances are cash and credits owed to wholesalers and insurers, and their stabilization this quarter matches the steadier pricing seen in Fanapt.
Money owed by wholesalers for shipped drugs rose 10.5% from $54.6 million at the end of 2025 and 1.0% from $59.7 million last quarter. Over the first nine months of 2026, receivables grew slightly faster than the 8.3% increase in total revenue as the pharmaceutical company stocked wholesalers for NEREUS.
Weighted average shares outstanding rose 2.3% from 59.1 million a year ago and 0.4% from 60.2 million in the second quarter. The drugmaker does not buy back stock and issues shares for employee compensation, which slowly increases the share count while the business operates at a net loss.
🔮 Guidance
Cut. Management removed the $290 million top end of its prior $240 million to $290 million range and kept only the $240 million floor, which represents 11.1% growth over 2025 by our math. With $172.1 million booked in the first nine months, the floor leaves at least $67.9 million for the fourth quarter, or 18.7% growth over last year's fourth quarter by our math.
❓ Key Questions
Why did Vanda drop its individual product sales ranges?
In the first two quarters of 2026, the company gave full-year sales targets for Fanapt and BYSANTI ($150–170 million), NEREUS ($10–30 million) and other drugs ($80–90 million). Dropping all three alongside the $290 million ceiling leaves unclear which product fell behind plan.
How much constrained NEREUS wholesaler stock sold to patients?
In the second quarter, wholesalers bought $15.2 million of NEREUS, but Vanda held back $12.6 million from revenue until patients filled prescriptions. Management has not yet said whether third-quarter revenue of $1.6 million came from new orders or releasing that reserve.
Will Vanda report BYSANTI sales separately from Fanapt?
With BYSANTI launching in the fourth quarter and Fanapt losing exclusivity at the end of 2027, investors need standalone BYSANTI revenue and net-price figures to see if patients are switching before generic Fanapt arrives.
How much more will quarterly operating expenses fall in 2027?
Operating expenses dropped by $21 million from the second quarter to $93.3 million, but the company still burned $29.5 million of cash. Management has not given a dollar target for 2027 spending or legal fees across its FDA disputes.